Samjin to transfer a technology of anti-AIDS virus.

Published: 2005-10-19 06:57:00

Updated: 2005-10-19 06:57:00

Samjin pharmaceutical company announced on Oct. 14 that the company had agreed with Imquest Pharmaceuticals in the United States to transfer the anti-AIDS virus compound "SJ-3366" which was developed and patented by Samjin under the exclusive and packaged technology transfer agreement.

Samjin ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK